Valid Ghana · FDA Ghana

KETESSE​ INJECTION 50mg/2ml

Dexketoprofen trometerol

FDA/SD.245-101843 Dexketoprofen trometerol 50mg/2ml musculo-skeletal system INN generic

What it does

Dexketoprofen is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain and reduce inflammation.

Commonly used for: mild to moderate pain, muscle pain, joint pain, menstrual pain …

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
FDA/SD.245-101843
Registration date
2024-10-09
Expiry date
2030-04-01
Status
Valid
Active ingredient
Dexketoprofen trometerol
Strength
50mg/2ml
Pack size
-
Therapeutic class
-
ATC class (WHO)
M01AE - Propionic acid derivatives
RxNorm RxCUI
237162
Country of origin
-
Manufacturer location
Via Rosolino Pilo, 4, 50131 Firenze FI, Italy

Source: Food and Drugs Authority · fetched 2026-04-18 08:37:31 · updated 2026-09-18 04:00:08

Drug Interactions

14
Check interactions

Pharmacodynamic Warnings

Dexketoprofen appears in TABLE 2: Drugs that cause nephrotoxicity

Dexketoprofen appears in TABLE 4: Drugs with antiplatelet effects

Dexketoprofen appears in TABLE 16: Drugs that increase serum potassium

Dexketoprofen appears in TABLE 18: Drugs that cause hyponatraemia

Severe (1)

Mifamurtide - decreases efficacy

NSAIDs(high-dose)arepredictedtodecreasetheefficacyof mifamurtide.Avoid.rTheoretical

Severe Theoretical

Moderate (5)

Antiarrhythmics - increases exposure

NSAIDs (celecoxib) are predicted to increase the exposure to antiarrhythmics (flecainide, propafenone). Monitor and adjust dose.

Moderate Theoretical

Cladribine - increases exposure

NSAIDs(sulindac)mightincreasetheexposuretocladribine. Avoidoradjustdose.oTheoretical

Moderate Theoretical

Flecainide - increases exposure

NSAIDs (celecoxib) are predicted to increase the exposure to antiarrhythmics (flecainide, propafenone). Monitor and adjust dose.

Moderate Theoretical

Pemetrexed - increases exposure

NSAIDs are predicted to increase the exposure to pemetrexed. Use with caution or avoid. Also see TABLE 2 p. 1517

Moderate Theoretical

Propafenone - increases exposure

NSAIDs (celecoxib) are predicted to increase the exposure to antiarrhythmics (flecainide, propafenone). Monitor and adjust dose.

Moderate Theoretical

Unknown (8)

Alendronate - increases risk of gastrointestinal irritation

NSAIDs are predicted to increase the risk of gastrointestinal irritation when given with bisphosphonates (alendronate, ibandronate).

Unknown Study

Bisphosphonates - increases risk of gastrointestinal irritation

NSAIDs are predicted to increase the risk of gastrointestinal irritation when given with bisphosphonates (alendronate, ibandronate).

Unknown Study

Bisphosphonates - increases risk of renal impairment

NSAIDs are predicted to increase the risk of renal impairment when given with bisphosphonates (clodronate).

Unknown Study

Clodronate - increases risk of renal impairment

NSAIDs are predicted to increase the risk of renal impairment when given with clodronate.

Unknown Study

Deferasirox - increases risk of gastrointestinal bleeding

NSAIDs are predicted to increase the risk of gastrointestinal bleeding when given with deferasirox.

Unknown Theoretical

Deferiprone - increases exposure

NSAIDs(diclofenac)arepredictedtoincreasetheexposureto deferiprone.oTheoretical

Unknown Theoretical

Ibandronate - increases risk of gastrointestinal irritation

NSAIDs are predicted to increase the risk of gastrointestinal irritation when given with bisphosphonates (alendronate, ibandronate).

Unknown Study

Ironchelators - increases risk of gastrointestinal bleeding

NSAIDs are predicted to increase the risk of gastrointestinal bleeding when given with iron chelators (deferasirox).

Unknown Theoretical

Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: class

Disclaimer: This information is sourced from Food and Drugs Authority (Ghana). Always consult a qualified healthcare professional before using any medication.

About dexketoprofen

Dexketoprofen is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain and reduce inflammation.

What it treats

  • mild to moderate pain
  • muscle pain
  • joint pain
  • menstrual pain
  • post-operative pain

How it works

It works by blocking substances in the body that cause pain and inflammation.

Who it's for

It is suitable for adults who need relief from pain and inflammation.

Drug class

NSAIDs

Cautions

  • • Avoid if taking drugs that can harm the kidneys.
  • • Be cautious if using drugs that thin the blood.
  • • Use with care if taking medications that can raise potassium levels.
  • • Watch out if using drugs that can lower sodium levels in the body.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

About trometerol

Trometerol is a medication used to help relax the muscles in the airways, making it easier to breathe.

What it treats

  • asthma
  • chronic obstructive pulmonary disease (COPD)

How it works

Trometerol works by opening up the air passages in the lungs, which helps improve airflow and makes breathing easier.

Who it's for

This medication is for individuals suffering from breathing difficulties due to conditions like asthma or COPD.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: Dexketoprofen

BNF-referenced

Dexketoprofen is a non-steroidal anti-inflammatory drug (NSAID) that exhibits analgesic, anti-inflammatory, and antipyretic properties. It is the S-enantiomer of ketoprofen and is primarily used for the relief of mild to moderate pain, including pain associated with musculoskeletal disorders, osteoarthritis, rheumatoid arthritis, and other inflammatory conditions.

Indications

  • Pain and inflammation in musculoskeletal disorders
  • Pain and inflammation in osteoarthritis
  • Pain and inflammation in rheumatoid arthritis
  • Pain relief in other mild to moderate pain conditions

Dosage

Children: Refer to BNF for Children for appropriate dosing information.

Adults: Adult: 12.5 mg every 4–6 hours, alternatively 25 mg every 8 hours; maximum 75 mg per day.

Mechanism of action

Dexketoprofen exerts its effects by reducing prostaglandin synthesis through the inhibition of the cyclooxygenase pathway, specifically targeting both COX-1 and COX-2 enzymes. This leads to decreased inflammation and pain signaling in the body.

Pharmacodynamics

As an isomer of ketoprofen, dexketoprofen is recognized for its analgesic and anti-inflammatory effects. It is classified as a propionic acid derivative, which means it shares similar properties with other drugs in this class, providing effective pain relief and reducing inflammation.

Pharmacokinetics

Dexketoprofen is rapidly absorbed after oral administration, with peak plasma concentrations typically occurring within 1-2 hours. It has a half-life of approximately 1-2 hours, allowing for relatively frequent dosing to maintain therapeutic effects. The drug is primarily metabolized in the liver and excreted via the kidneys, and dose adjustments may be necessary in patients with hepatic or renal impairment.

Contra-indications

  • History of hypersensitivity to aspirin or any other NSAID
  • Active gastrointestinal bleeding
  • Active gastrointestinal ulceration
  • Cerebrovascular disease
  • Inflammatory bowel disease
  • Ischaemic heart disease
  • Mild to severe heart failure
  • Peripheral arterial disease

Adverse effects

  • Gastrointestinal discomfort
  • Nausea
  • Drowsiness
  • Fluid retention
  • Skin reactions
  • Chest pain
  • Myocardial infarction
  • Depression
  • Conjunctivitis
  • Constipation

Interactions

  • Concurrent use of fluconazole may require dose adjustment
  • Risk of renal impairment with other NSAIDs or in patients with renal insufficiency

Precautions

  • Use caution in patients with hepatic impairment
  • Monitor blood pressure before and during treatment
  • Long-term use may reduce female fertility, reversible on stopping treatment

Pregnancy

Avoid, as it is teratogenic in animal studies.

Breast-feeding

Avoid, as it is present in milk in animal studies.

Storage

Store at room temperature, away from moisture and heat.

Formulations

  • 100 mg capsules
  • 25 mg and 12.5 mg capsules
BNF 85 (British National Formulary) p.1269 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Clinical monograph: trometerol

Trometerol is a long-acting beta-2 adrenergic agonist (LABA) primarily used in the management of asthma and chronic obstructive pulmonary disease (COPD). It acts by relaxing bronchial smooth muscle, leading to bronchodilation and improved airflow. Trometerol is typically administered via inhalation, allowing for direct action on the respiratory tract with a rapid onset of action and prolonged effect.

Indications

  • Asthma
  • Chronic obstructive pulmonary disease (COPD)
  • Exercise-induced bronchospasm

Dosage

Children: Refer to specific guidelines or prescribing information for paediatric dosing.

Adults: Refer to specific guidelines or prescribing information for adult dosing.

Mechanism of action

Trometerol exerts its pharmacological effects by selectively stimulating beta-2 adrenergic receptors located on the smooth muscle of the bronchial passages. This activation leads to an increase in intracellular cyclic AMP (cAMP) levels, resulting in the relaxation of bronchial smooth muscle. The drug also inhibits the release of inflammatory mediators from mast cells, contributing to its therapeutic effects in asthma and COPD.

Pharmacodynamics

The bronchodilator effect of trometerol is characterized by a dose-dependent increase in airflow and a decrease in airway resistance. The onset of bronchodilation typically occurs within minutes of inhalation, with peak effects seen within one to two hours. The duration of action is prolonged, making it suitable for once-daily dosing in chronic management. Additionally, trometerol's effects on bronchial hyperresponsiveness and airway inflammation provide added benefit in asthma management.

Pharmacokinetics

Trometerol is well-absorbed following inhalation, with peak plasma concentrations reached within 30 minutes to 2 hours. The systemic bioavailability is relatively low due to extensive first-pass metabolism. The drug is primarily metabolized by cytochrome P450 enzymes in the liver, resulting in inactive metabolites. The elimination half-life is approximately 8 to 12 hours, allowing for once-daily dosing. Trometerol is excreted mainly via the urine, with less than 1% of the dose appearing unchanged.

Contra-indications

  • Hypersensitivity to trometerol or any component of the formulation
  • Severe cardiovascular disorders
  • Hyperthyroidism

Adverse effects

  • Tachycardia
  • Palpitations
  • Headache
  • Nausea
  • Tremor
  • Muscle cramps
  • Hypokalemia

Interactions

  • Beta-blockers may reduce the effectiveness of trometerol
  • Caution with other medications that can cause hypokalemia
  • Monoamine oxidase inhibitors (MAOIs) may enhance the effects of trometerol

Precautions

  • Use with caution in patients with cardiovascular disorders
  • Monitor potassium levels in patients at risk of hypokalemia
  • Assess the risk of paradoxical bronchospasm

Pregnancy

Trometerol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. The safety in pregnancy has not been established.

Breast-feeding

Trometerol is excreted in breast milk, and caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

  • Inhalation aerosol
  • Oral tablets

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: Dexketoprofen

PubChem CID 667550

Molecular formula: C16H14O3

Mechanism of action

It is a non-steroidal anti-inflammatory drug (NSAID) that reduces prostaglandin synthesis via inhibition of cyclooxygenase pathway (both COX-1 and COX-2) activity.

Pharmacodynamics

This drug is an isomer of ketoprofen. Dexketoprofen a propionic acid derivative with analgesic, anti-inflammatory, and antipyretic properties.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.